Connect with us


Tilray (TLRY) Will Now Export Medical Marijuana from Portugal to Germany for Cannamedical



Tilray (TLRY) Will Now Export Medical Marijuana from Portugal to Germany for Cannamedical
- Ad -

Today, Tilray Inc. has announced another European deal through its subsidiary Tilray Portugal.

This is part of the company’s efforts to diversify internationally as legalization in Canada fails to see a surge in revenue.

Tilray’s Portuguese arm inked a contract to supply German consumers a wholesale shipment of medicinal marijuana to Cannamedical Pharma GmbH. Cannamedical has a license to supply cannabis to patients via a network of 2,500 clinics and pharmacies nationally.

According to the agreement, over $3 million worth of medicinal grade marijuana will be exported from Portugal to Germany later this fall. This will mark the initial major shipment from the company’s newly-opened Cantanhede campus.

The site was given GMP certification earlier this summer, and has been host to an array of local political figures who tour the facility as employment drive causes worker hiring by Tilray Portugal triple in digits.

Brendan Kennedy, the Chief Executive Officer of Tilray, stated that his team believes the 2.5 million square feet of cultivation and Europe’s processing space will help at cutting down costs and improve profit margins while hedging against risks related to regulation.

Besides the indoor growing facility, Tilray recently leased twenty hectares of outdoor growing space in Portugal’s Alentejo area to ramp production efforts further. Cannabis grown in this outdoor space will then be shipped to the Portuguese campus to be processed, packaged, and distributed to European customers.

Europe is not Tilray’s focus market for international expansion. In the recent month, the company has been importing Cannabidiol (CBD) capsules to the southern border to the United States for new clinical trials.

Several clinical studies and major research projects on the effectiveness of CBD are now underway in the U.S. as the FDA is expected to come up with more strict regulations as the product gains more popularity.

Andrew is a full-time professional writer in Canada with over 8 years of esteemed experience. He is one of the best cannabis health researchers, polished legal investigators and active CBD news reporters we have at TOC. While being featured in hundreds of health, technology, science, and even bitcoin publications; Andrew's now on the frontline of the Canadian cannabis culture and will continue breaking down everything so easily your grandma can understand hemp and CBD.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.